Clinical Trial Update: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating panitumumab, regorafenib, and TAS-102 in patients with metastatic and/or unresectable RAS wild-type colorectal cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Adenocarcinoma
• Colorectal Cancer
• Rectal Adenocarcinoma
• Unresectable Colorectal Cancer

Drugs mentioned

• Lonsurf (trifluridine/tipiracil)
• Stivarga (regorafenib)
• Vectibix (panitumumab)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-05-21